Skip to main content

Search
Profile

Julie R. Park, MD

|
Julie R. Park, MD

Hematology-Oncology

On staff since October 1996

Children's Title: Fellowship Program Director; Thomas Bradley Armstrong Endowed Chair in Pediatric Cardiology

Academic Title: Professor of Pediatrics, UW School of Medicine; Associate, Clinical Research Division, Fred Hutchinson Cancer Research Center

Research Center: Center for Clinical and Translational Research

Making a Difference

Recommendations

HeatherRedmond, WA07.10.13
Dr. Park did a wonderful job in her medical treatment of my daughter! We began the journey full of fears and worries, and we are so fortunate to have had the best possible outcome. I firmly believe that much of this is due to Dr. Park's wealth of experience, close monitoring and her willingness to listen to my concerns. I always feel that my daughter's best interests are Dr. Park's primary concern, and she has always been very compassionate and caring towards me - even when I was having a hard time coming to grips with what was happening. Anyone who has Dr. Park as their child's oncologist is very lucky to have her!
Recommend Dr. Julie Park

Overview

Board Certification(s)
Pediatric Hematology-Oncology
Medical/Professional School
University of Vermont College of Medicine, Burlington
Clinical Interests

Neuroblastoma, Novel therapies, Supportive care guidelines for care of oncologic patients, Post-transplant lymphoproliferative disease

Research Description

I am an active member of the Children's Oncology Group (COG) Consortium, coordinating the center's participation in clinical trials for treatment of neuroblastoma and non-Hodgkin lymphoma. As the oncology division director of Advanced Developmental Therapeutics, I oversee participation in national NIH-funded Phase I clinical research consortia, including the COG Phase I Consortium and the New Approaches to Neuroblastoma Therapy (NANT) Consortium.

My primary research focus is to discover novel therapies for the treatment of high-risk pediatric neuroblastoma using both adoptive immunotherapy and novel molecularly targeted approaches. I am the principal investigator for a national randomized Phase III trial within COG for treatment of newly diagnosed high-risk neuroblastoma.

Research Focus Area

Cancer

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
Seattle Magazine Top Doctor - 2013Seattle Magazine 2013
Seattle's Top DocSeattle Met Magazine 2013
Seattle Magazine Top Doctor - 2012Seattle Magazine Top Doctor - 2012Seattle Magazine 2012
U.S. News Top DoctorU.S. News and World Report 2012
Benjamin Towne Endowed Chair in NeuroblastomaBenjamin Towne Foundation 2009

Publications

Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621).
Pediatric blood & cancer , 2013 Dec 18
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Cancer , 2013 Oct 15: 119(20)3718-26
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
The lancet oncology , 2013 Sep: 14(10)999-1008
A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.
Bone marrow transplantation , 2013 Jul: 48(7)947-52
Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
Pediatric blood & cancer , 2013 Jun: 60(6)985-93
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine , 2013 Apr: 54(4)541-8
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
Pediatric blood & cancer , 2013 Mar: 60(3)363-70
About the benefits of immunotherapy for high-risk neuroblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2013 Feb 10: 31(5)649-50
Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons , 2012 Nov: 12(11)3069-75
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2012 Sep 15: 18(18)5081-9
Functional genomics identifies therapeutic targets for MYC-driven cancer.
Proceedings of the National Academy of Sciences of the United States of America , 2012 Jun 12: 109(24)9545-50
Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients.
Journal of the Pediatric Infectious Diseases Society , 2012 Jun: 1(2)103-111
Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
Drug metabolism and disposition: the biological fate of chemicals , 2012 Jan: 40(1)54-63
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Nov 20: 29(33)4351-7
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
Cancer chemotherapy and pharmacology , 2011 Oct: 68(4)1057-65
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
Pediatric blood & cancer , 2011 Aug: 57(2)275-82
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Aug 1: 3623-9
Neuroblastoma: biology, prognosis, and treatment.
Hematology/oncology clinics of North America , 2010 Feb: 65-86
High-risk neuroblastoma: a therapy in evolution.
Pediatric hematology and oncology , 2009 Nov: 539-48
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Mar 10: 1290-6
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Pediatric blood & cancer , 2009 Jan: 44-50
Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.
Journal of clinical pharmacology , 2009 Jan: 88-102
Influenza-associated morbidity in children with cancer.
Pediatric blood & cancer , 2008 May: 983-7
Neuroblastoma: biology, prognosis, and treatment.
Pediatric clinics of North America , 2008 Feb: 97-120, x
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
Molecular therapy : the journal of the American Society of Gene Therapy , 2007 Apr: 825-33
Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2005 Sep 20: 6481-8
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Pediatric blood & cancer , 2004 Oct: 571-9
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2004 Aug 15: 5335-41
Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
Cancer , 2004 Mar 15: 1268-75
Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2003 Apr: 286-91
Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Medical and pediatric oncology , 2003 Feb: 93-8

Presentations

Presentations TitleEventLocationDate
Infectious Complications of Pediatric CancerAdvanced Oncology Nursing unknownOct. 1, 2009
Accessing Novel Therapies and Navigating the Maze - The Pediatric Oncologist's PerspectiveAmerican Society of Clinical Oncology, Educational SessionOrlando, FLJune 1, 2009
Infectious Complications of Pediatric CancerAdvanced Oncology Nursing unknownJune 1, 2009
Targeting Treatment to Improve Outcomes for Childhood CancerCircle of Care Symposium, Seattle Children’s HospitalSeattle, WAMay 1, 2009
Infectious Complications of Pediatric CancerAdvanced Oncology Nursing unknownFeb. 1, 2009
Infectious Complications of Pediatric CancerAdvanced Oncology NursingunknownFeb. 1, 2009

Research Funding

Grant TitleGrantorAmountAward Date
Children's Oncology Group - Phase I pilot consortium formed under the Children's Oncology Group to conduct Phase I clinical research trialsNIH/NCI - U01 CA097452-06Aug. 1, 2012 - July 31, 2017
Pharmacogenetics of Cyclophosphamide ADRs in ChildrenNIH/NCI - R21 CA162059-01Sept. 1, 2011 - Aug. 31, 2013
Children's Oncology Group Chair's Grant - Chair Neuroblastoma, Chair ANBL0532NIH/NCI - U10 CA098543-05March 1, 2008 - Feb. 28, 2013
NIH-U10 CA098543-05NIHMarch 1, 2008 - Feb. 28, 2013
Children's Oncology Group - Phase I Study ChairNIH/NCI - U10 CA97452-06Aug. 1, 2007 - July 31, 2011
Translation Research for Pediatric Solid Tumors Alex’s Lemonade Stand Foundation $200,000.00July 1, 2007
Phase I-II Safety & Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed-Refractory Solid TumorsWyeth PharmaceuticalsJan. 17, 2007 - Jan. 16, 2010
Genetic Predisposition to Chemotherapy Toxicity in Children Receiving CyclophosphamideCHRMC Gift Income Genetic Predisposition to Chemotherapy Toxicity in Children Receiving Cyclophosphamide EndowmentOct. 1, 2005
Biology and Therapy of High Risk NeuroblastomaNIH/NCI - P01 CA81403-08June 1, 2003 - May 31, 2013
Novel therapies for high-risk neuroblastomaNIH/NCI - K23 CA87058-05July 1, 2002 - June 30, 2007
Targeted Hematopoietic Irradiation for Treatment of High Risk Neuroblastoma7. CHRMC Gift Income Targeted Hematopoietic Irradiation for Treatment of High Risk Neuroblastoma EndowmentDec. 1, 1999

Primary Office

Seattle Children's
MB.8.501 - Hematology-Oncology
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2106

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options